Grace Therapeutics Inc Ordinary Shares GRCE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
-
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
-
Grace Therapeutics Shares Fall After FDA Flags Issues in Aneurysm Treatment Application
Trading Information
- Previous Close Price
- $2.41
- Day Range
- $2.33–2.46
- 52-Week Range
- $1.79–5.18
- Bid/Ask
- $2.44 / $2.47
- Shares Outstanding
- 16.27M
- Market Cap
- $40.03M
- Volume/Avg
- 61,432 / 536,253
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.gracetx.com
Valuation
|
Metric
|
GRCE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.60 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
GRCE
Financial Strength
|
Metric
|
GRCE
|
|---|---|
Quick Ratio | 7.92 |
Current Ratio | 8.10 |
Interest Coverage | — |
Quick Ratio
GRCE
Profitability
|
Metric
|
GRCE
|
|---|---|
Return on Assets (Normalized) | −11.46% |
Return on Equity (Normalized) | −12.24% |
Return on Invested Capital (Normalized) | −13.11% |
Return on Assets
GRCE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$XRk%D | LOCK|nb#C | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|g!@&<< | LOCK|$@MM | $70B | |||
| argenx SE ADR
ARGX
| LOCK|@<>rVK& | LOCK|ynj | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^@><&&> | LOCK|NBk% | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#ddV<#s | LOCK|%$N | $37B | |||
| Moderna Inc
MRNA
| LOCK|@!Lg&&# | LOCK|<sM | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Wc>R<%Zm | LOCK|<W%n | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|&QS@WbS | LOCK|#> | $23B | |||
| Incyte Corp
INCY
| LOCK|&p>jNmS | LOCK|sF | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|R&^q@DC | LOCK|F>p | $16B |
United States